Stop Meth Labs and Enhance Patient Access Act of 2015

Bill: 114-hr-3968
Sponsor: full_name: Rep. Guinta, Frank C. [R-NH-1]
Introduced: 2015-11-05
Policy area: Crime and Law Enforcement
Subjects: Business records

Drug trafficking and controlled substances

Government information and archives

Prescription drugs

Retail and wholesale trades
Latest action: action_date: 2015-12-04
text: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

Summaries:
action_date: 2015-11-05
action_desc: Introduced in House
text: <p><b>Stop Meth Labs and Enhance Patient Access Act of 2015 </b></p> <p>This bill amends the Controlled Substances Act to revise the standard used by the Drug Enforcement Administration (DEA) to determine whether to exempt a scheduled listed chemical product from certain applicable requirements. (A scheduled listed chemical product is a nonprescription drug product that contains ephedrine, pseudoephedrine, or phenylpropanolamine.)</p> <p>Currently, the DEA may exempt retail sales of a scheduled listed chemical product from certain requirements (e.g., daily sales limits) if the product cannot be used to illegally manufacture methamphetamine. This bill allows the DEA to exempt retail sales of a scheduled listed chemical product from such requirements if it is not practical by processes known to be employed by clandestine laboratory operators to use the product to illegally manufacture methamphetamine. </p>

tv_txt: I 114th CONGRESS 1st Session H. R. 3968 IN THE HOUSE OF REPRESENTATIVES November 5, 2015 Mr. Guinta introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act to allow the Attorney General to exempt a product from certain requirements if the Attorney General determines that it is not practical by processes known to be employed by clandestine laboratory operators to use the product in the illicit manufacture of methamphetamine.

1. Short title This Act may be cited as the Stop Meth Labs and Enhance Patient Access Act of 2015 . 2. Exemption for products if it is not practical by processes known to be employed by clandestine laboratory operators to use the products in the illicit manufacture of methamphetamine Section 310(e)(3) of the Controlled Substances Act ( 21 U.S.C. 830(e)(3) ) is amended by striking if the Attorney General determines that the product cannot be used in the illicit manufacture of methamphetamine and inserting if the Attorney General determines that it is not practical by processes known to be employed by clandestine laboratory operators to use the product in the illicit manufacture of methamphetamine .